FMS:NYE-Fresenius Medical Care AG & Co. KGaA (USD)

COMMON STOCK | Medical Care Facilities | NYE

Last Closing Price

USD 40.66

Change

+0.37 (+0.92)%

Market Cap

USD 23.60B

Volume

0.22M

Avg Analyst Target

USD 40.08 (-1.44%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCA HCA Healthcare, Inc

-2.46 (-0.99%)

USD82.42B 18.63 10.09
OSH Oak Street Health, Inc

+0.64 (+1.06%)

USD14.50B N/A N/A
AGL agilon health, inc

-0.33 (-0.92%)

USD13.97B N/A N/A
UHS Universal Health Services, Inc

-2.93 (-1.91%)

USD13.09B 13.03 8.36
DVA DaVita Inc

+0.01 (+0.01%)

USD12.75B 18.57 10.55
EHC Encompass Health Corporation

-1.07 (-1.34%)

USD7.96B 26.25 12.04
THC Tenet Healthcare Corporation

-2.25 (-3.11%)

USD7.72B 19.17 7.40
CHE Chemed Corporation

+1.82 (+0.38%)

USD7.54B 23.50 15.88
SEM Select Medical Holdings Corpor..

-1.41 (-3.51%)

USD5.42B 16.98 10.24
CANO Cano Health, Inc

+0.57 (+5.21%)

USD5.24B N/A N/A

ETFs Containing FMS

Symbol Name Weight Mer Price(Change) Market Cap
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
ZPRL:F SSgA SPDR ETFs Europe II .. 0.00 % 0.30 %

+0.28 (+0.62%)

USD0.08B
EL4X:XETRA Deka DAXplus Maximum Divi.. 0.00 % 0.30 %

+0.12 (+0.18%)

USD0.24B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.17% 25% F 21% F
Dividend Return 2.01% 100% A+ 58% F
Total Return -0.16% 25% F 23% F
Trailing 12 Months  
Capital Gain -10.56% 5% F 7% F
Dividend Return 3.39% 88% B+ 52% F
Total Return -7.17% 5% F 8% F
Trailing 5 Years  
Capital Gain -8.30% 33% F 25% F
Dividend Return 7.19% 100% A+ 21% F
Total Return -1.11% 33% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 0.39% 30% F 29% F
Dividend Return 1.37% 88% B+ 33% F
Total Return 1.76% 30% F 23% F
Risk Return Profile  
Volatility (Standard Deviation) 19.57% 90% A- 57% F
Risk Adjusted Return 8.99% 30% F 21% F
Market Capitalization 23.60B 96% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.67 61% D- 50% F
Price/Book Ratio 1.69 84% B 54% F
Price / Cash Flow Ratio 5.58 54% F 62% D-
EV/EBITDA 9.40 74% C 68% D+
Management Effectiveness  
Return on Equity 10.50% 52% F 61% D-
Return on Invested Capital 8.36% 57% F 70% C-
Return on Assets 4.20% 55% F 71% C-
Debt to Equity Ratio 60.63% 58% F 56% F
Technical Ratios  
Short Ratio 1.70 79% C+ 56% F
Short Percent 0.12% 96% A 93% A
Beta 1.01 75% C 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector